



Claim 1 (Currently Amended). A compound of the following formula:



wherein  $R_2$  and  $R_4$  are H;

$R_{15}$  is N-substituted amino, or of the following formula:



[[ ; ]] or


$R_{16}$  is H, alkyl, acyl, alkoxy, aryl, amino, halogen, HET; wherein HET is chosen from pyrrolidine, morpholine, piperazine, piperidine; with the proviso that  $R_{15}$  is not  $\text{NH}_2$  when  $R_{16}$  is H;


and pharmaceutically acceptable salts thereof.

Claim 2-9 (Canceled).

Claim 10 (Original). A compound of claim 1, wherein HET is pyrrolidine, morpholine.

Claim 11 (Previously Presented). A compound of claim 1 having the following structure:







Claim 12-15 (Canceled).

Claim 16 (Currently Amended). A method of inhibiting or treating ~~amebic infections,~~  
~~including~~ giardiasis, comprising:

administering a therapeutically effective amount of a compound of claim 1 and a  
pharmaceutically acceptable carrier to a patient in need thereof.



Claim 17 (Currently Amended). A compound of claim 1, of the following formula:






and pharmaceutically acceptable salts thereof.

Claim 18 (Currently Amended). A compound of claim 1, of the following formula:



and pharmaceutically acceptable salts thereof.

Claim 19 (Currently Amended). A compound of claim 1, of the following formula:



and pharmaceutically acceptable salts thereof.